최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기멤브레인 = Membrane Journal, v.30 no.1, 2020년, pp.9 - 20
최태환 (한양대학교 에너지공학과) , 박호범 (한양대학교 에너지공학과)
Membranes are used in most processes of biopharmaceutical production. It is used for pretreatment of other processes, separation of impurities in the process, virus removal, control of products concentration and buffer solution exchange. Virus filters play an important role in ensuring product effic...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
바이오의약품이 변화에 민감한 이유는? | 바이오의약품은 사람이나 다른 생물체에서 유래된 것을 원료 또는 재료로 제조한 의약품으로서 보건위생상 특별한 주의가 필요한 의약품을 말한다[1]. 바이오의약품은 보통 합성의약품에 비해 복잡한 고분자 구조를 가지고 있고, 크기가 크며, 생물체를 원료로 하여 복잡한 제조공정을 거쳐야 되기 때문에 변화에 민감한 편이다. 또한, 합성의약품은 화학물질의 비율을 알면 쉽게 합성 및 복제가 가능한 반면에 바이오의약품은 배양기술과 환경, 방법에 따라 전혀 다른 물질이 나올 수 있어 복제가 쉽지 않은 특징이 있다[2-4]. | |
바이오의약품이란 무엇인가? | 바이오의약품은 사람이나 다른 생물체에서 유래된 것을 원료 또는 재료로 제조한 의약품으로서 보건위생상 특별한 주의가 필요한 의약품을 말한다[1]. 바이오의약품은 보통 합성의약품에 비해 복잡한 고분자 구조를 가지고 있고, 크기가 크며, 생물체를 원료로 하여 복잡한 제조공정을 거쳐야 되기 때문에 변화에 민감한 편이다. | |
바이오의약품 제조에서 바이러스 오염이 끼치는 영향은 무엇인가? | 이러한 오염 사고는 의약품의 안정성과 효능에 심각한 지장을 줄 뿐만 아니라, 생산 제품 자체의 손실, 예상 판매량 손실, 오염 제거 및 규제 비용에서 경제적으로 상당한 손해를 초래한다. 일반적으로 오염을 제거하기 위한 비용은 10,000 L 규모의 세포 배양에 6~8백만 달러에 이르는 것으로 추정된다[9]. |
"Regulations on Product Approval and Examination of Biological Products", MFDS (2019).
"Overview of Biological Products", FDA (CDER) (2013).
"Biopharmaceutical Industry Trend Report", KoBIA (2018).
D. B. Yim, "Biopharmaceutical Market Opportunity and Global Competitiveness", Samjong KPMG ERI Co., 59 (2016).
P. Roberts, "Virus safety in bio products", J. Chem. Technol. Biotechnol., 59(1), 110 (1994).
"Points to consider in the manufacture and testing of monoclonal antibody products for human use, department of health and human services", FDA (CBER) (1996).
"Guidance for industry: Q5A viral safety evaluation of biotechnology products derived from cell lines of human or animal origin", ICH (1999).
M. Bakhshayeshirad, "Performance characteristics of virus filtration membranes: Protein fouling and virus retention", Penn State Univ. (2011).
S. Liu, M. Carroll, R. Iverson, C. Valera, J. Vennari, K. Turco, R. Piper, R. Kiss, and H. Lutz, "Development and qualification of a novel virus removal filter for cell culture applications", Biotechnol. Prog., 16, 425 (2000).
"Guideline on validation of biopharmaceuticals manufacture processes", MFDS (2016).
A. A. Shukla, M. R. Etzel, and S. Gadam, "Process Scale Bioseparation for the Biopharmaceutical Industry", Taylor & Francis, New York, NY, 297 (2007).
W. P. Olson, "Separations Technology: Pharmaceutical and Biotechnology Applications", Interpharm Press, Buffalo Grove, IL, 122 (1995).
A. S. Rathore and A. Shirke, "Recent developments in membrane-based separations in biotechnology processes: Review", Prep. Biochem. Biotechnol., 41, 398 (2011).
R. V. Reis and A. Zydney, "Bioprocess membrane technology", J. Membr. Sci., 297, 16 (2007).
M. A. Serabian and A. M. Pilaro, "Safety assessment of biotechnology -derived pharmaceuticals: ICH and beyond", Toxicol. Pathol., 27, 27 (1999).
A. S. Rosenberg, "Effects of protein aggregates: An immunologic perspective", AAPS J., 8, 501 (2006).
"Guideline on assessing virus stability of biotechnology products from cell lines", MFDS (2002).
D. Gail, "QA/QC for viral clearance", Genetic Engineering & Biotechnology News (www.genengnews.com), 26 (2006).
S. Chandra, A. Groener, and F. Feldman, "Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products", Thromb Res., 105, 391 (2002).
P. Roberts, "Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products", Biologicals, 28, 29 (2000).
J. L. Lundblad and R. L. Seng, "Inactivation of lipid-enveloped viruses in proteins by caprylate", Vox Sang., 60, 75 (1991).
F. Brown, "An overview of the inactivation of FMDV and the implications when residual virus is present in vaccines", Dev. Biol. Stand., 75, 37 (1991).
M. F. Bachmann, T. M. Kundig, C. P. Kalberer, H. Hengartner, and R. M. Zinkernagel, "Formalin inactivation of vesicular stomatitis virus impairs T-cell but not T-help-independent B-cell responses", J. Virol., 67, 3917 (1993).
A. Scheidler, K. Rokos, T. Reuter, R. Ebermann, and G. Pauli, "Inactivation of viruses by beta-propiolactone in human cryo poor plasma and IgG concentrates", Biologicals, 26, 135 (1998).
W. R. Alonso, S. Trukawinski, M. Savage, R. A. Tenold, and D. J. Hammond, "Viral inactivation of intramuscular immune serum globulins", Biologicals, 28, 5 (2000).
S. A. Lawrence, "Beta-propiolactone: Viral inactivation in vaccines and plasma products", PDA J. Pharm. Sci. Technol., 54, 209 (2000).
M. Korneyeva, J. Hotta, W. Lebing, R. S. Rosenthal, L. Franks, and S. R. Petteway Jr, "Enveloped virus inactivation by caprylate: A robust alternative to solvent-detergent treatment in plasma derived intermediates", Biologicals, 30, 153 (2002).
H. Dichtelmuller, D. Rudnick, and M. Kloft, "Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution", Biologicals, 30, 135 (2002).
Parenteral Drug Association (PDA), "PDA Technical Report No. 41: Virus filtration", PDA J. Pharm. Sci. Technol., 59 (2005).
M. Azari, J. A. Boose, K. E. Burhop, T. Camacho, J. Catarello, A. Darling, A. A. Ebeling, T. N. Estep, L. Pearson, S. Guzder, J. Herren, K. Ogle, J. Paine, K. Rohn, R. Sarajari, C. S. Sun, and L. Zhang, "Evaluation and validation of virus removal by ultrafiltration during the production of diaspirin crosslinked haemoglobin (DCLHb)", Biologicals, 28, 81 (2000).
T. Urase, K. Yamamoto, and S. Ohgaki, "Effect of pore structure of membranes and module configuration on virus retention", J. Membr. Sci., 115, 21 (1996).
I. Laursen, G. Houen, P. Hojrup, N. Brouwer, L. B. Krogsoe, L. Blou, and P. R. Hansen, "Second-generation nanofiltered plasma-derived mannan-binding lectin product: Process and characteristics", Vox Sang., 92, 338 (2007).
K. Furuya, K. Murai, T. Yokoyama, H. Maeno, Y. Takeda, T. Murozuka, A. Wakisaka, M. Tanifuji and T. Tomono, "Implementation of a 20-nm pore-size filter in the plasma-derived Factor VIII manufacturing process", Vox Sang., 91, 119 (2006).
T. R. Kreil, A. Wieser, A. Berting, M. Spruth, C. Medek, G. Polsler, T. Gaida, T. Hammerle, W. Teschner, H. P. Schwarz, and P. N. Barrett, "Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives", Transfusion, 46, 1143 (2006).
T. Burnouf and M. Radosevich, "Nanofiltration of plasma-derived biopharmaceutical products", Haemophilia, 9, 24 (2003).
A. Johnston, A. MacGregor, S. Borovec, M. Hattarki, K. Stuckly, D. Anderson, N. H. Goss, A. Oates, and E. Uren, "Inactivation and clearance of viruses during the manufacture of high purity factor IX", Biologicals, 28, 129 (2000).
https://planova.ak-bio.com, February 25 (2020).
K. H. Oshima, T. W. Comans, A. K. Highsmith, and E. W. Ades, "Removal of human immunodeficiency virus by an 0.04-micron membrane filter", J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 8, 64 (1995).
K. H. Oshima, "Evans-Strickfaden T. T., Highsmith A. K., Ades E. W., The use of a microporous polyvinylidene fluoride (PVDF) membrane filter to separate contaminating viral particles from biologically important proteins", Biologicals, 24, 137 (1996).
K. H. Oshima, T. T. Evans-Strickfaden, and A. K. Highsmith, "Comparison of filtration properties of hepatitis B virus, hepatitis C virus and simian virus 40 using a polyvinylidene fluoride membrane filter", Vox Sang., 75, 181 (1998).
H. Aranha-Creado, K. Oshima, S. Jafari, G. Howard, and H. Brandwein, "Virus retention by a hydrophilic triple-layer PVDF microporous membrane filter", PDA J. Pharm. Sci. Technol., 51, 119 (1997).
H. Aranha-Creado, J. Peterson, and P. Y. Huang, "Clearance of murine leukaemia virus from monoclonal antibody solution by a hydrophilic PVDF microporous membrane filter", Biologicals, 26, 167 (1998).
G. Miesegaes, S. Lute, H. Aranha, and K. Brorson, "Virus retentive filters", in: M. C. Flickinger(Ed.), Encyclopedia of Industrial Biotechnology, Bioprocess, Bioseparation, and Cell Technology, Wiley, New York, USA (2010)
https://shop.pall.com/us/en/biotech/filtration, February 25 (2020).
A. DiLeo, A. Allegrezza, and S. Builder, "High resolution removal of virus from protein solutions using a membrane of unique structure", Nat. Biotechnol., 10, 182 (1992).
A. J. DiLeo, D. A. Vacante, E, and F. Deane, "Size exclusion removal of model mammalian viruses using a unique membrane system, Part I: Membrane qualification", Biologicals, 21, 275 (1993).
A. J. DiLeo, D. A. Vacante, E, and F. Deane, "Size exclusion removal of model mammalian viruses using a unique membrane system, Part II: Model qualification and process simulation", Biologicals, 21, 287 (1993).
B. Hughes, A. Bradburne, A. Sheppard, and D. Young, "Evaluation of anti-viral filters", Dev. Biol. Stand., 88, 91 (1996).
J. Parkkinen, A. Rahola, L. von Bonsdorff, H. Tolo, and E. Torma, "A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance", Vox Sang., 90, 97 (2006).
J. X. Zhou, F. Solamo, T. Hong, M. Shearer, and T. Tressel, "Viral clearance using disposable systems in monoclonal antibody commercial downstream processing", Biotechnol. Bioeng., 100, 488 (2008).
H. Brough, C. Antoniou, J. Carter, J. Jakubik, Y. Xu, and H. Lutz, "Performance of a novel viresolve NFR virus filter", Biotechnol. Prog., 18, 782 (2002).
https://www.merckmillipore.com/KR/ko/, February 25 (2020).
K. Tarrach, A. Meyer, J. E. Dathe, and H. Sun, "The effect of flux decay on a 20 nm nanofilter for virus retention", Biopharm Int., 20, 58 (2007).
https://www.sartorius.com, February 25 (2020).
S. Emory, "Principles of integrity testing hydrophilic microporous membranes", Pharm. Technol., 13, 68 (1989).
A. Depalma, "Making Filtration Work", Bioprocess Int., 17, 4 (2019).
J. Bartels, A. G. Batista, S. Kroll, M. Maas, and K. Rezwan, "Hydrophobic ceramic capillary membranes for versatile virus filtration", J. Membr. Sci., 570-571, 85 (2019).
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.